- Home
- KPLT vs BOLD Comparison
KPLT vs BOLD Comparison
Compare KPLT & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | KPLT | BOLD |
|---|---|---|
| Founded | 2012 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.9M | 28.0M |
| IPO Year | N/A | 2024 |
Fundamental Metrics
Financial Performance| Metric | KPLT | BOLD |
|---|---|---|
| Price | $6.77 | $1.26 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | ★ $10.00 | $4.00 |
| AVG Volume (30 Days) | 68.7K | ★ 118.6K |
| Earning Date | 11-12-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $280,839,000.00 | N/A |
| Revenue This Year | $21.42 | N/A |
| Revenue Next Year | $15.48 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 16.15 | N/A |
| 52 Week Low | $5.50 | $1.00 |
| 52 Week High | $24.34 | $2.77 |
Technical Indicators
Market Signals| Indicator | KPLT | BOLD |
|---|---|---|
| Relative Strength Index (RSI) | 51.77 | 54.14 |
| Support Level | $6.67 | $1.21 |
| Resistance Level | $7.03 | $1.35 |
| Average True Range (ATR) | 0.40 | 0.07 |
| MACD | 0.08 | 0.00 |
| Stochastic Oscillator | 55.47 | 52.38 |
Price Performance
Historical ComparisonAbout KPLT Katapult Holdings Inc.
Katapult Holdings Inc. is a technology-driven lease-to-own platform that integrates with omni-channel retailers and e-commerce platforms to power the purchase of everyday durable goods for underserved U.S. non-prime consumers. It is an e-commerce-focused FinTech company offering a lease-purchase solution to consumers and enabling essential transactions at the merchant point of sale. Katapult is associated with hundreds of retailers across the United States.
About BOLD Boundless Bio Inc.
Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.